lsHITA DRUGS & INDUSTRIES LTD.Corp.   Off.:   401     3rd   Eye   11.   Opp.   Parimal   Garden    C    G    Road,  Ahmedabad-380006
Regd.   Office    a    Factory    :    179/I,  Vasna-lyava.   Tal     Sanand,   Disc        Ahmedabad
E-mail  : ishicadru!s®Ermail.com  I   info®ishitadrugs.com   I  UFLL  :  wwwjshitadrugs±gm
Phone  :  +917226995613/14/15  I    +9179  4002  3839
Date: 19.11.2025
TO'
Department of Corpo rate Services,
BSE Limited.
Floor No. 25, Pliiroze |eejeebhoy Towers,
Dalal Street, Mumbal-400 001
Scrit] Code: 524400
Dear Sir/Madam,
Sub: Disclosure under reEnilation 29fzl of SEEBI rsiubstantial Acquisition of Shares and
Takeoversl Renllations. 2011
With Reference to the captioned subject, please find enclosed the disclosure uhder regulation 29(2)
of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011:
a)           Acquisition of 807 shares of Rs.10/-each by lshita pharmaceuticals, related party of lshita
Drugs and Industries Ltd.
Please take the above disclosure on record.
ThankingYou,
For, Ishita Drugs and Industries Limited
Abha Agrawal
Director
•Chlr bas\c dngs in the sc:rm:e Of humanrty zuortdunde .
CIN  No. L24231 GJ1992PLC017054
D a  a D-U-N-S Number -65.018-0359

HsffiITife PEIARE©EuITE@ifeE£Phone: 91 -79 -26468353/7886, Email: ishitaDharmal980@gmail.com
Factoii/: 65/1, GIDC Industrial Estate, Wadhawan -363035, Surendranegar, India.
Date: 18.11.2025
SciriD Code: 524400
TO'
Department of Corporate Services,
BSE Limited.
Floor No. 25, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-4bo 001
Ishita Drugs & Industries Ltd.
Office No: 401, 3rd Eye ||,
Opp. Parimal Garden, C.G. Road,
Ahmedabad - 380 006
Dear Sir/Madam,
.Sub: DisclosLlre under ref!iilation 29T21 of SEBI Isiibstantia[ Acoilisition of SliaTes &
takeoverst Refndations. Z011
With Reference to the captioned subject lshita Pharmaceuticals, related party of lshita Drugs and
Industries  Limited,  do  hereby inform you  that we  have aeduired  807  shares  of Rs.  10/-  each  Of
lshita Drugs & Industries Ltd.
Please  find  enclosed  the  necessary  disclosure  as  required  under  regulation  29(2)  of  the  SEBl
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Kindly, take the above information on your record.
Thanking you,
Yours Faithfully,

ESHITyffi EDHifeREffi©yEuryE©ffiH£Phone: 91 -79 -26468353/7886,  Email: harmal980 mail.com
Factory: 65/1, GIDC Industrial Estate, Wadhawan -363035, Surendranagar, India.
resunderRegulation29r21ofSEBIrsubstatantfa]
and Takeovers` Ref!ulations. 2011
hares
Name of the Target Company CI'C) Ishita Drugs and Industries Limited
Name(s)   of  the  acquirer  and   Persons  Acting  in [shita Pharmaceuticals
Concert rpAcl with the acquirer
Whether         the          acquirer          b elongs          to Related Party of the Target Company
Promoter/Promoter group
Name(s)   of   the   Stock   Exchange(s)   where   the BSE Limited
shares ofTC are Listed
Details of the acquisition / disposal as follows Number % w.r,t. totalshare/votingcapitalwhereverapplicabler*1% w.r.t. totaldilutedshare/votingcapitaloftheTC(I")
Before the acquisition under consideration,
25353 0.85 0.85
holding of :
a)   Shares carrying voting rights
b)   Shares in the nature of encumbrance
NilNil NilNil NilNil(pledge/ lien/ non-disposal undertaking/
others)
c)   Voting rights IVR) otherwise than by
shares
d)   Warrants/convertible          securities/any Nil25353 Nil0.85 Nil0.85other    instrument    that    entitles    the
acquirer to receive shares carrying voting
rights in the T C  (specify holding in each
category)
e)    Total (a+b+c+d)

HSEEITife PEIARE©EuHTn©fflE£Phone: 91 -79 -26468353/886, Email:  ishitaDharmal980@gmail.com
Factory: 65/1, GIDC Industrial Estate, Wadhawan -363035, Surendranegar, India.
Details of acquisition
807 0.03 0.03
a)   Shares          carrying         voting          rights
acquired/soid
b)   VRs   acquired   /sold   otherwise   than   by
Nil Nil Nilshares
c)   Warrants/convertible          securities/any NilNil NilNil NilNilother    instrument    that    entitles    the
acquirer to receive shares carrying voting
rights  in the  TC  (specify holding in  each
category) acquired/sold
d)   Shares encumbered / invoked/released by
the acquirer 807 0.03 0.03e)    Total ra+b+c+dl
After the acquisition, holding of:
26160 0.88 0.88a)   Shares carrying voting rights
b)   Shares encumbered with the acquirer NIL NIL NIL
c)   VRs otherwise than byshares NIL NII` NIL
d)   Warrants/convertible          securities/any NIL•26160 NIL0.88 NIL0.88
other     instrument    that    entitles    the
acquirer to receive shares carrying voting
rights  in the  TC  (specify holding in  each
category) after acquisition
e)    Total (a+b+c+d)
Mode of acquisition Open Market
Date of acquisition November 17, 2025
Equity share capital of the Target Company before Rs. 29903000/-(2990300 shares of Rs.10 each)
the said acquisition
Equity share capital  of the Target Company after Rs. 29903000/-(2990300 shares of Rs.10 each)
the said acquisition
Total  diluted  share/voting  capital  of  the  Target Rs. 29903000/-(2990300 shares of Rs.10 each)
Comt)any after the said acquisition
(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the
Stock Exchange under Clause 35 of the listing Agreement.
(**)   Diluted  share/voting  capital  means  the  total  number  of  shares  in  the  TC  assuming  full
conversion of the outstanding convertible securities/warrants into equity shares of the TC.

